1. Home
  2. BTDR vs NVAX Comparison

BTDR vs NVAX Comparison

Compare BTDR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTDR

Bitdeer Technologies Group

HOLD

Current Price

$12.05

Market Cap

3.1B

Sector

Technology

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$8.15

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTDR
NVAX
Founded
2021
1987
Country
Singapore
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
1.6B
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
BTDR
NVAX
Price
$12.05
$8.15
Analyst Decision
Strong Buy
Hold
Analyst Count
10
9
Target Price
$22.70
$11.33
AVG Volume (30 Days)
6.4M
3.1M
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
309.76
EPS
N/A
2.58
Revenue
N/A
$1,123,479,000.00
Revenue This Year
$72.51
N/A
Revenue Next Year
$40.84
N/A
P/E Ratio
N/A
$3.14
Revenue Growth
N/A
64.69
52 Week Low
$7.04
$5.80
52 Week High
$27.80
$11.85

Technical Indicators

Market Signals
Indicator
BTDR
NVAX
Relative Strength Index (RSI) 61.68 41.59
Support Level $11.96 $8.01
Resistance Level $13.22 $8.45
Average True Range (ATR) 0.78 0.34
MACD 0.10 0.02
Stochastic Oscillator 70.84 36.72

Price Performance

Historical Comparison
BTDR
NVAX

About BTDR Bitdeer Technologies Group

Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: